Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Tiina Kasanen"'
Autor:
Jani Huuhtanen, Dipabarna Bhattacharya, Tapio Lönnberg, Matti Kankainen, Cassandra Kerr, Jason Theodoropoulos, Hanna Rajala, Carmelo Gurnari, Tiina Kasanen, Till Braun, Antonella Teramo, Renato Zambello, Marco Herling, Fumihiro Ishida, Toru Kawakami, Marko Salmi, Thomas Loughran, Jaroslaw P. Maciejewski, Harri Lähdesmäki, Tiina Kelkka, Satu Mustjoki
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-16 (2022)
T cell large granular lymphocytic leukemia (T-LGLL) is a lymphoproliferative disorder involving clonally expanded T cell clones and is not fully understood. Here the authors show that the rest of the immune repertoire is interconnected with the T-LGL
Externí odkaz:
https://doaj.org/article/f672b9429b1944109879f38760c24199
Autor:
Jani Huuhtanen, Mette Ilander, Bhagwan Yadav, Olli M.J. Dufva, Hanna Lähteenmäki, Tiina Kasanen, Jay Klievink, Ulla Olsson-Strömberg, Jesper Stentoft, Johan Richter, Perttu Koskenvesa, Martin Höglund, Stina Söderlund, Arta Dreimane, Kimmo Porkka, Tobias Gedde-Dahl, Björn T. Gjertsen, Leif Stenke, Kristina Myhr-Eriksson, Berit Markevärn, Anna Lübking, Andreja Dimitrijevic, Lene Udby, Ole Weis Bjerrum, Henrik Hjorth-Hansen, Satu Mustjoki
Publikováno v:
The Journal of Clinical Investigation, Vol 132, Iss 17 (2022)
In chronic myeloid leukemia (CML), combination therapies with tyrosine kinase inhibitors (TKIs) aim to improve the achievement of deep molecular remission that would allow therapy discontinuation. IFN-α is one promising candidate, as it has long-las
Externí odkaz:
https://doaj.org/article/41296f647a1141389dad7968d6690e57
Autor:
Anna Kreutzman, Bhagwan Yadav, Tim H. Brummendorf, Bjorn Tore Gjertsen, Moon Hee Lee, Jeroen Janssen, Tiina Kasanen, Perttu Koskenvesa, Kourosh Lotfi, Berit Markevärn, Ulla Olsson-Strömberg, Jesper Stentoft, Leif Stenke, Stina Söderlund, Lene Udby, Johan Richter, Henrik Hjorth-Hansen, Satu Mustjoki
Publikováno v:
OncoImmunology, Vol 8, Iss 9 (2019)
Changes in the immune system induced by tyrosine kinase inhibitors (TKI) have been shown to positively correlate with therapy responses in chronic myeloid leukemia (CML). However, only a few longitudinal studies exist and no randomized comparisons be
Externí odkaz:
https://doaj.org/article/d70460040d3747b5b862c7dbbae3b557
Autor:
Tiina Kelkka, Mikko Tyster, Sofie Lundgren, Xingmin Feng, Cassandra Kerr, Kohei Hosokawa, Jani Huuhtanen, Mikko Keränen, Bhavisha Patel, Toru Kawakami, Yuka Maeda, Otso Nieminen, Tiina Kasanen, Pasi Aronen, Bhagwan Yadav, Hanna Rajala, Hideyuki Nakazawa, Taina Jaatinen, Eva Hellström-Lindberg, Seishi Ogawa, Fumihiro Ishida, Hiroyoshi Nishikawa, Shinji Nakao, Jaroslaw Maciejewski, Neal S. Young, Satu Mustjoki
In immune aplastic anemia (IAA), severe pancytopenia results from the immune-mediated destruction of hematopoietic stem cells. Several autoantibodies have been reported, but no clinically applicable autoantibody tests are available for IAA. We screen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89b0ae054178b860b526a78bf5b6f4ee
http://hdl.handle.net/10138/347701
http://hdl.handle.net/10138/347701
Autor:
Tiina Kelkka, Mikko Tyster, Sofie Lundgren, Xingmin Feng, Cassandra Kerr, Kohei Hosokawa, Jani Huuhtanen, Mikko Keränen, Toru Kawakami, Bhavisha Patel, Yuka Maeda, Otso Nieminen, Tiina Kasanen, Pasi Aronen, Bhagwan Yadav, Hanna Rajala, Hideyuki Nakazawa, Taina Jaatinen, Eva Hellstrom-Lindberg, Seishi Ogawa, Fumihiro Ishida, Hiroyoshi Nishikawa, Shinji Nakao, Jaroslaw Maciejewski, Neal S. Young, Satu Mustjoki
In immune aplastic anemia (IAA), severe pancytopenia results from the immune-mediated destruction of hematopoietic stem cells. Several autoantibodies have been reported, but no clinically applicable autoantibody tests are available for IAA. We screen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::921ce0295c9b9bad6470c313559fe0e3
https://doi.org/10.21203/rs.3.rs-1653776/v1
https://doi.org/10.21203/rs.3.rs-1653776/v1
Autor:
Jani, Huuhtanen, Dipabarna, Bhattacharya, Tapio, Lönnberg, Matti, Kankainen, Cassandra, Kerr, Jason, Theodoropoulos, Hanna, Rajala, Carmelo, Gurnari, Tiina, Kasanen, Till, Braun, Antonella, Teramo, Renato, Zambello, Marco, Herling, Fumihiro, Ishida, Toru, Kawakami, Marko, Salmi, Thomas, Loughran, Jaroslaw P, Maciejewski, Harri, Lähdesmäki, Tiina, Kelkka, Satu, Mustjoki
Publikováno v:
Nature communications. 13(1)
T cell large granular lymphocytic leukemia (T-LGLL) is a rare lymphoproliferative disorder of mature, clonally expanded T cells, where somatic-activating STAT3 mutations are common. Although T-LGLL has been described as a chronic T cell response to a
Autor:
Hanna Rajala, Renato Zambello, Till Braun, Thomas P. Loughran, Satu Mustjoki, Tiina Kasanen, Cassandra M Kerr, Tiina Kelkka, Toru Kawakami, Harri Lähdesmäki, Antonella Teramo, Jason Theodoropoulos, Jaroslaw P. Maciejewski, Jani Huuhtanen, Marco Herling, Dipabarna Bhattacharya, Marko Salmi, Tapio Lönnberg, Fumihiro Ishida, Matti Kankainen
Publikováno v:
Blood. 138:1318-1318
Background: T-cell large granular lymphocytic leukemia (T-LGLL), a rare lymphoproliferative disorder of mature T cells, is characterized by the accumulation of activated effector T cells leading to a clonally restricted T-cell receptor (TCR) repertoi
Autor:
Oscar Brück, Kimmo Porkka, Satu Mustjoki, Marc Pelletier, Joel Wagner, Elena Orlando, Matti Kankainen, Olli Dufva, Karita Peltonen, Viviana Cremasco, Anna Kreutzman, Jay Klievink, Hanna Lähteenmäki, Harri Lähdesmäki, Mikael L. Rinne, Mika Kontro, Jani Huuhtanen, Tiina Kasanen, Catherine Anne Sabatos-Peyton, Mette Ilander
Publikováno v:
Blood. 138:801-801
Background The success of allogeneic stem cell transplantation supports the notion that immunotherapy can have curative potential in AML, but immune checkpoint therapies (e.g., anti-PD1) have shown only modest clinical efficacy. TIM3 is an immune-che
Autor:
Jay Klievink, Ulla Olsson-Strömberg, Satu Mustjoki, Mette Ilander, Taina Jaatinen, Rebecca Warfvinge, Harri Lähdesmäki, Henrik Hjorth-Hansen, Shady Adnan Awad, Jani Huuhtanen, Jason Theodoropoulos, Olli Dufva, Göran Karlsson, Anna Kreutzman, Tiina Kasanen, Andreas Burchert
Publikováno v:
Blood. 136:4-5
Only half of chronic myeloid leukemia (CML) patients in deep molecular remission are able to maintain treatment free remission (TFR) after tyrosine kinase inhibitor (TKI) discontinuation. Identifying predictive markers for TFR remains a key issue. Th
Autor:
Berit Markevärn, Kourosh Lotfi, Stina Söderlund, Jeroen Janssen, Johan Richter, Anna Kreutzman, Henrik Hjorth-Hansen, Bhagwan Yadav, Lene Udby, Satu Mustjoki, Moon Hee Lee, Bjørn Tore Gjertsen, Ulla Olsson-Strömberg, Jesper Stentoft, Tiina Kasanen, Tim H. Brümmendorf, Perttu Koskenvesa, Leif Stenke
Publikováno v:
Oncoimmunology
OncoImmunology, 8(9):e1638210. Landes Bioscience
Kreutzman, A, Yadav, B, Brummendorf, T H, Gjertsen, B T, Hee Lee, M, Janssen, J, Kasanen, T, Koskenvesa, P, Lofti, K, Markevärn, B, Olsson-Strömberg, U, Stentoft, J, Stenke, L, Söderlund, S, Udby, L, Richter, J, Hjorth-Hansen, H & Mustjoki, S 2019, ' Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line ', OncoImmunology, vol. 8, no. 9, e1638210 . https://doi.org/10.1080/2162402X.2019.1638210
e1638210
8:e1638210
Kreutzman, A, Yadav, B, Brummendorf, T H, Gjertsen, B T, Lee Hee, M, Janssen, J, Kasanen, T, Koskenvesa, P, Lofti, K, Markevärn, B, Olsson-Strömberg, U, Stentoft, J, Stenke, L, Söderlund, S, Udby, L, Richter, J, Hjorth-Hansen, H & Mustjoki, S 2019, ' Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line ', OncoImmunology, vol. 8, no. 9, e1638210 . https://doi.org/10.1080/2162402X.2019.1638210
OncoImmunology 8(9), e1638210 (2019). doi:10.1080/2162402X.2019.1638210
OncoImmunology, Vol 8, Iss 9 (2019)
OncoImmunology, 8(9):e1638210. Landes Bioscience
Kreutzman, A, Yadav, B, Brummendorf, T H, Gjertsen, B T, Hee Lee, M, Janssen, J, Kasanen, T, Koskenvesa, P, Lofti, K, Markevärn, B, Olsson-Strömberg, U, Stentoft, J, Stenke, L, Söderlund, S, Udby, L, Richter, J, Hjorth-Hansen, H & Mustjoki, S 2019, ' Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line ', OncoImmunology, vol. 8, no. 9, e1638210 . https://doi.org/10.1080/2162402X.2019.1638210
e1638210
8:e1638210
Kreutzman, A, Yadav, B, Brummendorf, T H, Gjertsen, B T, Lee Hee, M, Janssen, J, Kasanen, T, Koskenvesa, P, Lofti, K, Markevärn, B, Olsson-Strömberg, U, Stentoft, J, Stenke, L, Söderlund, S, Udby, L, Richter, J, Hjorth-Hansen, H & Mustjoki, S 2019, ' Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line ', OncoImmunology, vol. 8, no. 9, e1638210 . https://doi.org/10.1080/2162402X.2019.1638210
OncoImmunology 8(9), e1638210 (2019). doi:10.1080/2162402X.2019.1638210
OncoImmunology, Vol 8, Iss 9 (2019)
Changes in the immune system induced by tyrosine kinase inhibitors (TKI) have been shown to positively correlate with therapy responses in chronic myeloid leukemia (CML). However, only a few longitudinal studies exist and no randomized comparisons be